Skip to main content
Premium Trial:

Request an Annual Quote

Pathogenetix Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathogenetix, formerly called US Genomics, has raised about $1.5 million, it disclosed in a document filed with the US Securities Exchange Commission.

In an amended Form D, the Woburn, Mass.-based firm targets about $1.8 million in equity in the round. The target and amount raised to date are up from the $1.3 million target and amount raised that Pathogenetix had cited in an SEC filing last month. Pathogenetix also said in November that it sold $900,000 in debt instruments.

The company did not identify investors on the $1.8 million round but related persons listed include Augustine Lawlor, a managing partner at HealthCare Ventures; Steve Gullans, a managing director at Excel Venture Management; and Enrico Petrillo, also a managing director at Excel Venture Management. The three are also directors of Pathogenetix.

The company did not say how the funds will be used but said it is not in connection with a business combination, such as a merger, acquisition, or exchange offer.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.